Die Arbeitsgruppe „Kolon- / Rektum- und Dünndarmkarzinome“ ist eine der mitgliederstärksten und aktivsten Arbeitsgruppen der AIO. Sie hat mehr als 400 Kolleg*innen als aktive Mitglieder und zusätzlich mehr als 500 Interessierte für Studien in der Datenbank der AIO gelistet. In die interventionellen Studien wurden seit 2007 ungefähr 5000 Patient*innen eingeschlossen.

Hinzu kommen mehr als 12.000 Patient*innen, die in die Registerstudie COLOPREDICT PLUS 2.0 eingeschlossen wurden.

Die Studien der AIO sind traditionell unter besonderer Berücksichtigung der Durchführbarkeit insbesondere im ambulanten und niedergelassenen Bereich konzipiert.

Die internationale Wahrnehmung drückt sich auch darin aus, dass die Projekte der AIO Kolon-Gruppe auch in diesem Jahr wieder mit drei Vorträgen auf dem ASCO / ESMO sichtbar war, einem Update der PANAMA- Studie zur Erhaltungstherapie mit Panitumumab, 1 den Ergebnissen der RAMTAS- Studie (TAS-102 plus Ramucirumab) 2 und einer Analyse zum optimalen CT- Zeitpunkt aus Studien der AIO und der GONO 3.

Zu den aktuellen Kongress-Ergebnissen, die einen unmittelbaren Einfluss auf multidisziplinäre Behandlungsstrategien haben, wurden auch in diesem Jahr Statements zur Interpretation veröffentlicht:

• Stellungnahme zur Lebertransplantation beim metastasierten Kolonkarzinom
• Stellungnahme zur thermischen Ablation als Alternative und Ergänzung zur chirurgischen Resektion von Lebermetastasen (jeweils gemeinsam ACO, ARO).

Offene Studien

Lokalisierte Stadien

Die COLOPREDICT Plus 2.0 Plattform erfasst in einer Registerstudie die Patient*innen mit einem Kolonkarzinom oder hochsitzendem Rektumkarzinom.

In der CIRCULATE Studie wird die ctDNA gerichtete Therapie im Stadium II des Kolonkarzinoms untersucht.

Die ACO/ARO/AIO-18.2 Studie vergleicht beim Rektumkarzinom mit niedrigem Lokalrezidivrisiko (bis frühes T3-Stadium) die präoperative FOLFOX-Therapie mit einer adjuvanten Chemotherapie analog des Kolonkarzinoms.

OPTIPATH ist ein Projekt, das sich der Genauigkeit des präoperativen Stagings bei Patient*innen mit einem lokalisierten Kolonkarzinom widmet.

Metastasiertes kolorektales Karzinom

Die FIRE-9/PORT Studie soll die Frage einer adjuvanten Therapie nach Resektion oder Ablation von Metastasen klären.

Die FIRE-8 Studie vergleicht bei Patient*innen, die keine Kombinationschemotherapie in der Erstlinientherapie erhalten können/sollen, die Kombination aus TAS-102 mit einem EGFR-Antikörper oder Bevacizumab.

Die TROPHIT1- Studie randomisiert Patient*innen in eine Therapie mit dem Antikörper-Drug- Konjugat Sacituzumab-Govitecan oder die Standardbehandlung.

Die GOBLET Studie untersucht u.a. bei kolorektalen Patient*innen die Kombination aus einem onkolytischen Virus (Pelareorep) mit einem PD-L1 Antikörper.

In der MEFOX Studie prüft Methadon zusammen mit FOLFOX beim fortgeschrittenen kolorektalen Karzinom.

Projekte und Studien in Vorbereitung

Lokalisierte Stadien

Die ACO/ARO/AIO-23 Studie soll einen IL-1 Rezeptor Antagonisten beim Rektumkarzinom untersuchen.

PROTECTOR ist eine Phase III Studie und vergleicht die perioperative mit der adjuvanten Chemotherapie beim fortgeschrittenen, nicht metastasierten Kolonkarzinom.

Metastasierte Erkrankung

Die FIRE-XXL Studie wird die kontinuierliche vs. intermittierende Gabe von Cetuximab plus FOLFIRI untersuchen.

Die QUINTIS Studie randomisiert fortgeschrittene Patient:innen in Fruquitinib/Tislelizumab oder TAS-102/Bevacizumab.

Die Chemotherapie zwischen zwei Resektionsschritten wird in der RECONVERT Studie geprüft werden.

mFOLFIRINOX-SBA ist ein deutsches Projekt in europäischer Kooperation zur Frage der Therapieintensität beim Dünndarmkarzinom.

Das Qs-mCRC Projekt dient einer Erfassung mit dem Ziel der Qualitätssicherung in Deutschland. 

Nicht mehr rekrutierende Studien

MSI-H Kolonkarzinom

Die ANTONIO Studie hatte die Therapie mit einem PD-L1 Antikörper beim lokalisierten MSI-H Kolonkarzinom zur Frage. Die Rekrutierung ist abgeschlossen.

In der FIRE-6 Studie wurden Patient*innen mit FOLFIRI/Cetuximab und einer Avelumab-Erhaltungstherapie behandelt. Die Rekrutierung ist abgeschlossen.

Lokalisierte Erkrankung

In der ACO/ARO/AIO-18.1 Studie verglich bei der TNT des Rektumkarzinoms das „Rapido-Schema“ mit einer (Langzeit-) Radiochemotherapie gefolgt von einer Chemotherapie. Auch hier ist die Rekrutierung abgeschlossen.

Metastasierte Erkrankung

Die FIRE-4 Studie untersuchte die Wirksamkeit einer Cetuximab- Reexposition.

In der AIO-KRK-0117 Studie erhielten ältere Patient*innen Aflibercept plus 5-FU oder FOLFOX. Bei beiden Studien ist die Rekrutierung abgeschlossen und werden die Ergebnisse erwartet.

Publikationen 2024

Die Ergebnisse der kontinuierlichen interdisziplinären Zusammenarbeit beim Rektumkarzinom fanden ihren Ausdruck in zahlreichen Artikeln^{. 4–8} Die Ergebnisse der FIRE 4.5 Studie zur Therapie beim BRAF mutierten Kolonkarzinom wurden im JCO veröffentlicht. ⁹

Eine Publikation beschäftigte sich mit Biomarkern und dem Ansprechen auf Cetuximab bzw Bevacizumab und erschien in Nature Communications, ¹⁰ eine beschrieb eine Therapie bei NRAS G12C Mutation und wurde im JCO Prec Oncol gedruckt. ¹¹

Zur PANAMA- Studie konnten sekundäre Analysen durchgeführt werden – zur Frage der Lebensqualität bei in Bezug auf die dermatologischen Nebenwirkungen, zur Frage der Krankheitslast und dem Ansprechen, zur Tiefe des Ansprechens und zu Resistenzmutationen.^12–15 Ebenso konnten zur XELAVIRI Studie weitere Biomarker-Arbeiten veröffentlicht werden. ¹⁶

Aus der großen Registerstudie COLOPREDICT konnten Zwischenergebnisse publiziert werden¹⁸

Ebenso konnte die AIO Datenbank genutzt werden, um die Prognose von Patient*innen in verschiedenen AIO Studien (hier in Bezug auf die Tumorlokalisation und das Geschlecht) zu beschreiben.¹⁷

Literatur

1. Modest DP, Karthaus M, Fruehauf S, et al. FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses. J Clin Oncol. 2024;42(16_suppl):3506-3506. doi:10.1200/JCO.2024.42.16_suppl.3506
2. Kasper-Virchow S, Hofheinz RD, Stintzing S, et al. LBA25 Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316). Ann Oncol. 2024;35:S1218. doi:10.1016/j.annonc.2024.08.2264
3. Germani MM, Heinemann V, Rossini D, et al. 506O Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment: An analysis of eleven randomized trials by AIO and GONO. Ann Oncol. 2024;35:S430-S431. doi:10.1016/j.annonc.2024.08.575
4. Fokas E, Williams H, Diefenhardt M, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials. Eur J Cancer Oxf Engl 1990. 2024;210:114291. doi:10.1016/j.ejca.2024.114291
5. Diefenhardt M, Martin D, Fleischmann M, et al. Overall Survival After Treatment Failure Among Patients With Rectal Cancer. JAMA Netw Open. 2023;6(10):e2340256. doi:10.1001/ jamanetworkopen.2023.40256
6. Hofheinz RD, Herrle F, Dechow T, et al. mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214). ESMO Open. 2024;9(9):103703. doi:10.1016/ j.esmoop.2024.103703
7. Diefenhardt M, Martin D, Hofheinz RD, et al. Persistent Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Rectal Cancer. JAMA Netw Open. 2024;7(9):e2432927. doi:10.1001/jamanetworkopen.2024.32927
8. Hofheinz RD, Arnold D, Borner M, et al. Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer. Oncol Res Treat. Published online October 9, 2024:1-5. doi:10.1159/000541376
9. Stintzing S, Heinrich K, Tougeron D, et al. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(25):4143-4153. doi:10.1200/JCO.22.01420
10. Ohnmacht AJ, Stahler A, Stintzing S, et al. The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer. Nat Commun. 2023;14(1):5391. doi:10.1038/s41467-023-41011-4
11. Möhrmann L, Cuberi A, Brückmann S, et al. Response to (K)RASG12C and EGFR Inhibition in a Patient With NRASG12C -Mutated Rectal Cancer. JCO Precis Oncol. 2023;(7):e2200666. doi:10.1200/PO.22.00666
12. Sommerhäuser G, Kurreck A, Beck A, et al. Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212). Eur J Cancer Oxf Engl 1990. 2023;178:37-48. doi:10.1016/j.ejca.2022.09.011
13. Stahler A, Kind AJ, Sers C, et al. Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212). Clin Cancer Res Off J Am Assoc Cancer Res. 2024;30(7):1256-1263. doi:10.1158/1078-0432.CCR-23-3023
14. Sommerhäuser G, Karthaus M, Kurreck A, et al. Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212). Int J Cancer. 2024;154(5):863-872. doi:10.1002/ijc.34760
15. Ballhausen A, Karthaus M, Fruehauf S, et al. Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial. ESMO Open. 2024;9(7):103628. doi:10.1016/j.esmoop.2024.103628
16. Boukovala M, Modest DP, Ricard I, et al. Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110). ESMO Open. 2024;9(5):103374. doi:10.1016/j.esmoop.2024.103374
17. Alig AHS, Modest DP, Stintzing S, et al. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI. ESMO Open. 2024;9(9):103677. doi:10.1016/j.esmoop.2024.103677
18. Ekmekciu I, Zucha DM, Christmann J, et al. Exploring the molecular profile of localized colon cancer: Insights from the AIO Colopredict Plus (CPP) Registry. Front Oncol. 2024;14. doi:10.3389/fonc.2024.1434791

Stahler A,  Modest DP, Stintzing S, Borelli B, Keller T, Held S, Fischer von Weikersthal L, Müller L, Graeven U, Decker T, Heintges T, Kahl C, Hoppe B, Kiani A, Kaiser F, Schwaner I, Fruehauf S, Karthaus M, Trarbach T, Klauschen F, Horst D, Cremolini C, Heinemann V. Individual patient data meta-analysis of consensus molecular subtypes as biomarkers of first-line treatment in RAS wild-type metastatic colorectal cancer . J Clin Oncol, 2025. Accepted for publication.

Germani MM, Borelli B, Hashimoto T, Nakamura Y, Oldani S, Battaglin F, Bergamo F, Salvatore L, Stahler A, Antoniotti C, Shitara K, Venook A, Oki E, Muro K, Ugolini C, Soeda J, Lonardi S, Pietrantonio F, Lenz HJ, Modest DP, Yoshino T, Cremolini C. Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials. J Clin Oncol. 2025 Oct 10;43(29):3184-3197. doi: 10.1200/JCO-25-01003. Epub 2025 Sep 4. PMID: 40906970; PMCID: PMC12509457.

Ballhausen A, Morano F, Stahler A, Lonardi S, Kind AJ, Cremolini C, Swoboda S, Randon G, Horst D, Prisciandaro M, Alig AHS, Pircher CC, Jarosch A, Andena P, Kurreck A, Chiaramonte AA, Stintzing S, Pietrantonio F, Modest DP, Raimondi A. Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials. Br J Cancer. 2025 Nov;133(9):1297-1306. doi: 10.1038/s41416-025-03164-5. Epub 2025 Aug 28. PMID: 40877636; PMCID: PMC12572284.

Germani MM, Heinemann V, Rossini D, Fischer von Weikersthal L, Pietrantonio F, Heinrich K, Stahler A, Lonardi S, Kaiser F, Decker T, Salvatore L, Weiss L, Morano F, Fuchs M, Bergamo F, Antoniotti C, Masi G, Stintzing S, Frumento P, Cremolini C, Modest DP. Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments-analysis of 11 trials by AIO and GONO. Ann Oncol. 2025 Nov;36(11):1307-1318. doi: 10.1016/j.annonc.2025.08.001. Epub 2025 Aug 19.PMID: 40840710

AIO-KRK-0212: Ballhausen A, Swoboda S, Horst D, Fruehauf S, Graeven U, Müller L, Trarbach T, Fischer von Weikersthal L, Goekkurt E, Heinemann V, Kasper S, Kurreck A, Alig AHS, Reinacher-Schick AC, Bullinger L, Stahler A, Stintzing S, Jarosch A, Modest DP.Clin Cancer Res. 2025 Oct 1;31(19):4049-4058. doi: 10.1158/1078-0432.CCR-25-0879.PMID: 40736443

FIRE-3/AIO-KRK-0306: Weiss L, Stintzing S, Stahler A, Benedikt Westphalen C, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller CA, Kahl C, Seipelt G, Kullmann F, Heinrich K, Holch JW, Alig A, Jung A, Modest DP, Heinemann V.Eur J Cancer. 2025 May 15;221:115399. doi: 10.1016/j.ejca.2025.115399. Epub 2025 Apr 4.PMID: 40222201.

FIRE-3/AIO-KRK-0306: Holch JW, Ohnmacht AJ, Stintzing S, Heinrich K, Weiss L, Probst V, Stahler A, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser F, Heintges T, Kahl C, Kullmann F, Link H, Höffkes HG, Moehler M, Modest DP, Menden MP, Heinemann V.Eur J Cancer. 2025 May 2;220:115388. doi: 10.1016/j.ejca.2025.115388. Epub 2025 Mar 25.PMID: 40179821

FIRE-4 / AIO-KRK-0114: Stintzing S, Klein-Scory S, Fischer von Weikersthal L, Fuchs M, Kaiser F, Heinrich K, Modest DP, Hofheinz RD, Decker T, Gerger A, Angermeier S, Rumpold H, Dickhut A, Öhler L, Gruenberger B, Niedersuess-Beke D, Sandmann M, Winder T, Trojan J, Prager G, Held S, Kumbrink J, Schmiegel W, Baraniskin A, Heinemann V.J Clin Oncol. 2025 Apr 20;43(12):1463-1473. doi: 10.1200/JCO.24.01174. Epub 2025 Feb 4.PMID: 39903881 Clinical Trial.

PanaMa / AIO KRK 0212: Stahler A, Karthaus M, Fruehauf S, Graeven U, Müller L, Fischer von Weikersthal L, Caca K, Goekkurt E, Ballhausen A, Sommerhäuser G, Alig AHS, Held S, Jarosch A, Horst D, Reinacher-Schick A, Kasper S, Heinemann V, Stintzing S, Trarbach T, Modest DP.EClinicalMedicine. 2024 Dec 16;79:103004. doi: 10.1016/j.eclinm.2024.103004. eCollection 2025 Jan.PMID: 39802302

FIRE-4.5 / AIO-KRK-0116: Klein-Scory S, Baraniskin A, Schmiegel W, Mika T, Schroers R, Held S, Heinrich K, Tougeron D, Modest DP, Schwaner I, Eucker J, Pihusch R, Stauch M, Kaiser F, Kahl C, Karthaus M, Müller C, Burkart C, Stintzing S, Heinemann V.Mol Oncol. 2025 Feb;19(2):344-356. doi: 10.1002/1878-0261.13778. Epub 2024 Dec 4.PMID: 39630848 Free PMC article. Clinical Trial.

CAO/ARO/AIO-12: Kosmala R, Hammann AS, Paulus P, Zimmermann M, Wittig-Sauerwein A, Germer CT, Ghadimi M, Hofheinz RD, Diefenhardt M, Fokas E, Rödel C, Polat B; German Rectal Cancer Study Group. Int J Radiat Oncol Biol Phys. 2025 May 21:S0360-3016(25)00483-3. doi: 10.1016/j.ijrobp.2025.05.018. Online ahead of print.PMID: 40409541

CAO/ARO/AIO-12: Diefenhardt M, Kosmala R, Fleischmann M, Martin D, Hofheinz RD, Ghadimi M, Rödel C, Polat B, Fokas E. ESMO Open. 2025 Mar;10(3):104483. doi: 10.1016/j.esmoop.2025.104483. Epub 2025 Mar 7.PMID: 40056849

CAO/ARO/AIO-16: Gani C, Fokas E, Polat B, Ott OJ, Diefenhardt M, Königsrainer A, Böke S, Kirschniak A, Bachmann R, Wichmann D, Bitzer M, Clasen S, Grosse U, Hoffmann R, Götz M, Hofheinz RD, Germer E, Germer CT, Fietkau R, Martus P, Zips D, Rödel C. Lancet Gastroenterol Hepatol. 2025 Jun;10(6):562-572. doi: 10.1016/S2468-1253(25)00049-4.PMID: 40347958

ACO/ARO/AIO-22: Dapper H, Fleischmann M, Tselis N, Diefenhardt M, Hofheinz RD, Weiß C, Grabenbauer GG, Merten R, Grosu AL, Kirste S, Rieken S, Claßen J, Langer C, Kuhnt T, Schmidberger H, Ghadimi M, Giordano F, Nestle U, Koerber SA, Bock F, Geiger M, Polat B, Bruns CJ, Dieplinger G, Popp F, Zander T, Brunner T, Tribius S, Arnold D, Wurschi G, Piso P, Friede T, Hörner-Rieber J, Gkika E, Rödel C, Fokas E; German Rectal Cancer Study Group. Clin Transl Radiat Oncol. 2025 Apr 13;53:100958. doi: 10.1016/j.ctro.2025.100958. eCollection 2025 Jul.PMID: 40276115

ACO/ARO/AIO-22: Dapper H, Fleischmann M, Tselis N, Diefenhardt M, Hofheinz RD, Weiß C, Grabenbauer GG, Merten R, Grosu AL, Kirste S, Rieken S, Claßen J, Langer C, Kuhnt T, Schmidberger H, Ghadimi M, Giordano F, Nestle U, Koerber SA, Bock F, Geiger M, Polat B, Bruns CJ, Dieplinger G, Popp F, Zander T, Brunner T, Tribius S, Arnold D, Wurschi G, Piso P, Friede T, Hörner-Rieber J, Gkika E, Rödel C, Fokas E; German Rectal Cancer Study Group. ACO/ARO/AIO-22 - External beam radiotherapy combined with endorectal high-dose-rate brachytherapy in elderly and frail patients with rectal cancer: A prospective multicentre trial of the German Rectal Cancer Study Group. Clin Transl Radiat Oncol. 2025 Apr 13;53:100958. doi: 10.1016/j.ctro.2025.100958. PMID: 40276115; PMCID: PMC12020863

AIO-KRK-0214: Hofheinz RD, Herrle F, Dechow T, von Weikersthal LF, Welslau M, Lettmaier S, Burkart C, Kubicka S, Kochen L, Merx K, Krause K, Ebert M, Rödel C, Fokas E, Ghadimi M, Reissfelder C, Gaiser T. ESMO Open. 2025 Feb;10(2):104095. doi: 10.1016/j.esmoop.2024.104095. Epub 2024 Dec 16.PMID: 39986704

CAO/ARO/AIO-04: Gaedcke J, Sahrhage M, Ebeling M, Azizian A, Rühlmann F, Bernhardt M, Grade M, Bechstein WO, Germer CT, Grützmann R, Piso P, Hofheinz RD, Staib L, Beißbarth T, Kosmala R, Fokas E, Rödel C, Ghadimi M; German Rectal Cancer Study Group. Sci Rep. 2025 Feb 13;15(1):5401. doi: 10.1038/s41598-024-83105-z.PMID: 39948076

CAO/ARO/AIO-12: Williams H, Fokas E, Diefenhardt M, Lee C, Verheij FS, Omer DM, Lin ST, Dunne RF, Marcet J, Cataldo P, Polite B, Piso P, Polat B, Dapper H, Ghadimi M, Hofheinz RD, Qin LX, Saltz LB, Wu AJ, Gollub MJ, Smith JJ, Weiser MR, Rödel C, Garcia-Aguilar J; German Rectal Cancer Study Group; OPRA Consortium. Ann Oncol. 2025 May;36(5):543-547.

Diefenhardt M, Martin D, Hofheinz RD, Ghadimi M, Fokas E, Rödel C, Fleischmann M. JAMA Netw Open. 2024 Sep 3;7(9):e2432927. doi: 10.1001/jamanetworkopen.2024.32927.PMID: 39264626

COLOPREDICT PLUS / AIO-KRK-0413/ass: Ekmekciu I, Zucha DM, Christmann J, Wisser S, Heuer V, Sargin B, Hollerbach S, Lamberti C, Müller L, Lugnier C, Verdoodt B, Denz R, Terzer T, Feder I, Reinacher-Schick A, Tannapfel A, Tischoff I. Exploring the molecular profile of localized colon cancer: insights from the AIO Colopredict Plus registry. Front Oncol. 2024 Nov 19;14:1434791. doi: 10.3389/fonc.2024.1434791. PMID: 39628993; PMCID: PMC11612501.

AIO-YMO/KRK 520/ass: Lugnier C, Förster S, Sommerlatte S, Schoffer O, Christmann J, Kraeft AL, Terzer T, Kourti E, Overheu O, Schlageter E, Ekmekciu I, Uhl W, Biermann C, Müller L, Sinn M, Kasper-Virchow S, Modest D, Heinemann V, Schmitt J, Schildmann J, Tannapfel A, Reinacher-Schick A. Significant Alterations of Colorectal Cancer Care in the COVID-19 Pandemic With High Adherence to Quality Criteria in German Cancer Centers (CC) ‒ Data From the AIO CancerCOVID Consortium (AIO-YMO/KRK 520/ass). Clin Colorectal Cancer. 2025 Jun;24(2):218-230. doi: 10.1016/j.clcc.2025.01.001. Epub 2025 Jan 21. PMID: 39966037.

Seufferlein T, Lausser L, Stein A, Arnold D, Prager G, Kasper-Virchow S, Niedermeier M, Müller L, Kubicka S, König A, Büchner-Steudel P, Wille K, Berger AW, Kestler AMR, Kraus JM, Werle SD, Perkhofer L, Ettrich TJ, Kestler HA. Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer-Results of the prospective multicenter PERMAD trial. PLoS One. 2024 Jun 14;19(6):e0304324. doi: 10.1371/journal.pone.0304324. PMID: 38875244; PMCID: PMC11178165.

Modest DP, Karthaus M, Fruehauf S, et al. FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses. J Clin Oncol. 2024;42(16_suppl):3506-3506. doi:10.1200/JCO.2024.42.16_suppl.3506

Kasper-Virchow S, Hofheinz RD, Stintzing S, et al. LBA25 Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316). Ann Oncol. 2024;35:S1218. doi:10.1016/j.annonc.2024.08.2264

Germani MM, Heinemann V, Rossini D, et al. 506O Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment: An analysis of eleven randomized trials by AIO and GONO. Ann Oncol. 2024;35:S430-S431. doi:10.1016/j.annonc.2024.08.575

Fokas E, Williams H, Diefenhardt M, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials. Eur J Cancer Oxf Engl 1990. 2024;210:114291. doi:10.1016/j.ejca.2024.114291

Diefenhardt M, Martin D, Fleischmann M, et al. Overall Survival After Treatment Failure Among Patients With Rectal Cancer. JAMA Netw Open. 2023;6(10):e2340256. doi:10.1001/ jamanetworkopen.2023.40256

Hofheinz RD, Herrle F, Dechow T, et al. mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214). ESMO Open. 2024;9(9):103703. doi:10.1016/ j.esmoop.2024.103703

Diefenhardt M, Martin D, Hofheinz RD, et al. Persistent Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Rectal Cancer. JAMA Netw Open. 2024;7(9):e2432927. doi:10.1001/jamanetworkopen.2024.32927

Hofheinz RD, Arnold D, Borner M, et al. Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer. Oncol Res Treat. Published online October 9, 2024:1-5. doi:10.1159/000541376

Stintzing S, Heinrich K, Tougeron D, et al. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(25):4143-4153. doi:10.1200/JCO.22.01420

Ohnmacht AJ, Stahler A, Stintzing S, et al. The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer. Nat Commun. 2023;14(1):5391. doi:10.1038/s41467-023-41011-4

Möhrmann L, Cuberi A, Brückmann S, et al. Response to (K)RASG12C and EGFR Inhibition in a Patient With NRASG12C -Mutated Rectal Cancer. JCO Precis Oncol. 2023;(7):e2200666. doi:10.1200/PO.22.00666

Sommerhäuser G, Kurreck A, Beck A, et al. Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212). Eur J Cancer Oxf Engl 1990. 2023;178:37-48. doi:10.1016/j.ejca.2022.09.011

Stahler A, Kind AJ, Sers C, et al. Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212). Clin Cancer Res Off J Am Assoc Cancer Res. 2024;30(7):1256-1263. doi:10.1158/1078-0432.CCR-23-3023

Sommerhäuser G, Karthaus M, Kurreck A, et al. Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212). Int J Cancer. 2024;154(5):863-872. doi:10.1002/ijc.34760

Ballhausen A, Karthaus M, Fruehauf S, et al. Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial. ESMO Open. 2024;9(7):103628. doi:10.1016/j.esmoop.2024.103628

Boukovala M, Modest DP, Ricard I, et al. Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110). ESMO Open. 2024;9(5):103374. doi:10.1016/j.esmoop.2024.103374

Alig AHS, Modest DP, Stintzing S, et al. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI. ESMO Open. 2024;9(9):103677. doi:10.1016/j.esmoop.2024.103677

Ekmekciu I, Zucha DM, Christmann J, et al. Exploring the molecular profile of localized colon cancer: Insights from the AIO Colopredict Plus (CPP) Registry. Front Oncol. 2024;14. doi:10.3389/fonc.2024.1434791

Ballhausen A, Karthaus M, Fruehauf S, Graeven U, Müller L, König AO, von Weikersthal LF, Sommerhäu-ser G, Alig AHS, Goekkurt E, Meyer-Knees JW, Kurreck A, Stahler A, Held S, Kasper S, Heinrich K, Heine-mann V, Stintzing S, Trarbach T, Modest DP. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial. Eur J Cancer. 2023 Sep;190:112955. doi: 10.1016/j.ejca.2023.112955.

Büttelmann M, Hofheinz RD, Kröcher A, Ubbelohde U, Stintzing S, Reinacher-Schick A, Bornhäuser M, Folprecht G. Geriatric assessment and the variance of treatment recommendations in geriatric patients with gastrointestinal cancer-a study in AIO oncologists. ESMO Open. 2023 Feb;8(1):100761.

Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, Martinelli E; ESMO Guidelines Committee. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Electronic address: clinicalguidelines@esmo.org. Ann Oncol. 2023 Jan;34(1):10-32. doi: 10.1016/j.annonc.2022.10.003. Epub 2022 Oct 25.

Diefenhardt M, Fleischmann M, Martin D, Hofheinz RD, Piso P, Germer CT, Hambsch P, Grützmann R, Kirste S, Schlenska-Lange A, Ghadimi M, Rödel C, Fokas E; German Rectal Cancer Study Group . Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and ad-juvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized  phase II/III trials. Radiother Oncol. 2023 Feb;179:109455. doi: 10.1016/j.radonc.2022.109455.

Gerwert K, Schörner S, Großerueschkamp F, Kraeft AL, Schuhmacher D, Sternemann C, Feder IS, Wisser S, Lugnier C, Arnold D, Teschendorf C, Mueller L, Timmesfeld N, Mosig A, Reinacher-Schick A, Tannapfel A. Fast and label-free automated detection of microsatellite status in early colon cancer using artificial intelligence integrated infrared imaging. Eur J Cancer. 2023 Mar;182:122-131.

Heinrich K, Karthaus M, Fruehauf S, Graeven U, Mueller L, König AO, von Weikersthal LF, Caca K, Kretz-schmar A, Goekkurt E, Haas S, Alig AHS, Kurreck A, Stahler A, Held S, Sommerhäuser G, Heinemann V, Stintzing S, Trarbach T, Modest DP. Impact of sex on the efficacy and safety of panitumumab plus flu-orouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212). ESMO Open. 2023 Aug;8(4):101568. doi: 10.1016/j.esmoop.2023.101568.

Hofmann FO, Heinemann V, D'Anastasi M, Gesenhues AB, Hesse N, von Weikersthal LF, Decker T, Kiani A, Moehler M, Kaiser F, Heintges T, Kahl C, Kullmann F, Scheithauer W, Link H, Modest DP, Stintzing S, Holch JW. Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in me-tastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306. Eur Radiol. 2023 Feb;33(2):1174-1184.

Mäurer M, Staudacher J, Meyer R, Mäurer I, Lazaridis L, Müther M, Huber T, Sommer NP, Fleischmann DF, Käsmann L, Ziegler S, Kropf-Sanchen C, Wikert J, Pietzner K, Holzgreve A, Nestler T, Siech C, Sturm MJ, Sulzer S, Heinrich K, Stahler A; Young Oncologists United (YOU). Importance of interdisciplinarity in modern oncology: results of a national intergroup survey of the Young Oncologists United (YOU). J Cancer Res Clin Oncol. 2023 Sep;149(12):10075-10084. doi: 10.1007/s00432-023-04937-2.

Müller D, Schuhmacher D, Schörner S, Großerueschkamp F, Tischoff I, Tannapfel A, Reinacher-Schick A, Gerwert K, Mosig  Dimensionality reduction for deep learning in infrared microscopy: a comparative computational survey. Analyst. 2023 Sep 13. doi: 10.1039/d3an00166k. Online ahead of print. PMID: 37702617

Ohnmacht AJ, Stahler A, Stintzing S, Modest DP, Holch JW, Westphalen CB, Hölzel L, Schübel MK, Gal-hoz A, Farnoud A, Ud-Dean M, Vehling-Kaiser U, Decker T, Moehler M, Heinig M, Heinemann V, Men-den MP. The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer. Nat Commun. 2023 Sep 4;14(1):5391. doi: 10.1038/s41467-023-41011-4.

Pretzsch E, Heinemann V, Stintzing S, Bender A, Chen S, Holch JW, Hofmann FO, Ren H, Bösch F, Kü-chenhoff H, Werner J, Angele MK. EMT-Related Genes Have No Prognostic Relevance in Metastatic Colorectal Cancer as Opposed to Stage II/III: Analysis of the Randomised, Phase III Trial FIRE-3 (AIO KRK 0306; FIRE-3). Cancers (Basel). 2022 Nov 14;14(22):5596. doi: 10.3390/cancers14225596.

Reinacher-Schick A, Ebert MP, Piso P, Hüppe D, Schmitt J, Schildmann J. Effects of the Pandemic on the Care of Patients With Colorectal Cancer. Dtsch Arztebl Int. 2023 Aug 21;120(33-34):545-552.

Sommerhäuser G, Kurreck A, Beck A, Fehrenbach U, Karthaus M, Fruehauf S, Graeven U, Mueller L, Ko-enig AO, V Weikersthal LF, Goekkurt E, Haas S, Stahler A, Heinemann V, Held S, Alig AHS, Kasper S, Stint-zing S, Trarbach T, Modest DP. Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212). Eur J Cancer. 2023 Jan;178:37-48.

Sommerlatte S, Lugnier C, Schoffer O, Jahn P, Kraeft AL, Kourti E, Michl P, Reinacher-Schick A, Schmitt J, Birkner T, Schildmann J, Herpertz. Mental burden and moral distress among oncologists and oncology nurses in Germany during the third wave of the COVID-19 pandemic: a cross-sectional survey. J Cancer Res Clin Oncol. 2023 Aug;149(9):6211-6223.

Stahler A, Hoppe B, Na IK, Keilholz L, Müller L, Karthaus M, Fruehauf S, Graeven U, Fischer von Wei-kersthal L, Goekkurt E, Kasper S, Kind AJ, Kurreck A, Alig AHS, Held S, Reinacher-Schick A, Heinemann V, Horst D, Jarosch A, Stintzing S, Trarbach T, Modest DP. Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212). J Clin Oncol. 2023 Jun 1;41(16):2975-2987.

Stintzing S, Heinrich K, Tougeron D, Modest DP, Schwaner I, Eucker J, Pihusch R, Stauch M, Kaiser F, Kahl C, Karthaus M, Müller C, Burkart C, Reinacher-Schick A, Kasper-Virchow S, Fischer von Weikersthal L, Krammer-Steiner B, Prager GW, Taieb J, Heinemann V. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study. J Clin Oncol. 2023 Sep 1;41(25):4143-4153.

Torlot L, Jarzab A, Albert J, Pók-Udvari Á, Stahler A, Holch JW, Gerlinger M, Heinemann V, Klauschen F, Kirchner T, Kumbrink J, Küster B, Jung A. Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance. J Cancer Res Clin Oncol. 2023 Feb;149(2):669-682.

Arends CM, Dimitriou S, Stahler A, Hablesreiter R, Strzelecka PM, Stein CM, Tilgner M, Saiki R, Ogawa S, Bullinger L, Modest DP, Stintzing S, Heinemann V, Damm F. Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial. Blood. 2022 Mar 10;139(10):1593-1597.

Betzler J, Piso P, Hofheinz RD, Reissfelder C. Multizentrische, randomisiert-kontrollierte Studien der ACO/AIO/ARO Chirurg. 2022 Apr;93(4):409-412.   

Collienne M, Loghmani H, Heineman TC, Arnold D GOBLET: a phase I/II study of pelareorep and atezolizumab +/- chemo in advanced or metastatic gastrointestinal cancers. .Future Oncol. 2022 Aug;18(26):2871-2878.

Diefenhardt M, Schlenska-Lange A, Kuhnt T, Kirste S, Piso P, Bechstein WO, Hildebrandt G, Ghadimi M, Hofheinz RD, Rödel C, Fokas E; German Rectal Cancer Study Group. Development and Validation of a Predictive Model for Toxicity of Neoadjuvant Chemoradiotherapy in Rectal Cancer in the CAO/ARO/AIO-04 Phase III Trial. Cancers (Basel). 2022 Jul 27;14(15):3658.

Diefenhardt M, Martin D, Ludmir EB, Fleischmann M, Hofheinz RD, Ghadimi M, Kosmala R, Polat B, Friede T, Minsky BD, Rödel C, Fokas E. Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited. Cancers (Basel). 2022 Sep 12;14(18):4425.

Fischer LE, Stintzing S, von Weikersthal LF, Modest DP, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Giessen-Jung C, Uhlig J, Peuser B, Denzlinger C, Stahler A, Weiss L, Heinrich K, Held S, Jung A, Kirchner T, Heinemann V. Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3. Br J Cancer. 2022 Sep;127(5):836-843. doi: 10.1038/s41416-022-01854-y.

Fleischmann M, Diefenhardt M, Nicolas AM, Rödel F, Ghadimi M, Hofheinz RD, Greten FR, Rödel C, Fokas E; German Rectal Cancer Study Group.ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group. Clin Transl Radiat Oncol. 2022 Apr 6;34:99-106

Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Kirste S, Jacobasch L, Allgäuer M, Flentje M, Germer CT, Grützmann R, Hildebrandt G, Schwarzbach M, Bechstein WO, Sülberg H, Friede T, Gaedcke J, Ghadimi M, Hofheinz RD, Rödel C; German Rectal Cancer Study Group. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol. 2022 Jan 1;8(1):e215445

Folprecht G, Reinacher-Schick A, Weitz J, Lugnier C, Kraeft AL, Wisser S, Aust DE, Weiss L, von Bubnoff N, Kramer M, Thiede C, Tannapfel A. The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217). Clin Colorectal Cancer. 2022 Jun;21(2):170-174

Hofmann FO, Heinemann V, D'Anastasi M, Gesenhues AB, Hesse N, von Weikersthal LF, Decker T, Kiani A, Moehler M, Kaiser F, Heintges T, Kahl C, Kullmann F, Scheithauer W, Link H, Modest DP, Stintzing S, Holch J. Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306. Eur Radiol. 2022 Aug 17. doi: 10.1007/s00330-022-09053-2.

Kurreck A, Heinemann V, Fischer von Weikersthal L, Decker T, Kaiser F, Uhlig J, Schenk M, Freiberg-Richter J, Peuser B, Denzlinger C, Graeven U, Heinrich K, Held S, Stahler A, Alig AHS, Jelas I, von Einem JC, Stintzing S, Giessen-Jung C, Modest DP. Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial. .Front Oncol. 2022 Feb 18;12:751453.

Modest DP, Karthaus M, Kasper S, Moosmann N, Keitel V, Kiani A, Uhlig J, Jacobasch L, Fischer V Weikersthal L, Fuchs M, Kaiser F, Lerchenmüller C, Sent D, Junghanß C, Held S, Lorenzen S, Kaczirek K, Jung A, Stintzing S, Heinemann V. FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314). Eur J Cancer. 2022 Sep;173:297-306. doi: 10.1016/j.ejca.2022.07.012.

Modest DP, Karthaus M, Fruehauf S, Graeven U, Müller L, König AO, Fischer von Weikersthal L, Caca K, Kretzschmar A, Goekkurt E, Haas S, Kurreck A, Stahler A, Held S, Jarosch A, Horst D, Reinacher-Schick A, Kasper S, Heinemann V, Stintzing S, Trarbach T. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). J Clin Oncol. 2022 Jan 1;40(1):72-82.

Moehler M, Folprecht G, Heinemann V, Holch JW, Maderer A, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Geißler M, Schulz-Abelius A, Linz B, Bernhard H, Paul A, Schmidtmann I, Potthoff K, Schimanski CC. Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3). Int J Cancer. 2022 Apr 15;150(8):1341-1349

Nöpel-Dünnebacke S, Jütte H, Denz R, Feder IS, Kraeft AL, Lugnier C, Teschendorf C, Collette D, Böhner H, Engel L, Mueller L, Hartmann F, Kaiser U, Bruch HR, Hollerbach S, Arnold D, Timmesfeld N, Tannapfel A, Reinacher-Schick ACauses of mortality in elderly UICC stage III colon cancer (CC) patients--Tumor-related death and competing risks from the German AIO colorectal study group Colopredict Plus (CPP) registry. Cancer Med. 2022 Apr;11(8):1735-1744.

Raschzok N, Stintzing S, Heinemann V, Rauch G, Ricke J, Guckenberger M, Kurreck A, Alig AHS, Stahler A, Bullinger L, Schmelzle M, Schöning W, Lurje G, Krenzien F, Haase O, Rau B, Gebauer B, Sauer IM, Pratschke J, Modest DP. FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer. BMC Cancer. 2022 Apr 2;22(1):359.

Sommerhäuser G, Kurreck A, Beck A, Fehrenbach U, Karthaus M, Fruehauf S, Graeven U, Mueller L, Koenig AO, V Weikersthal LF, Goekkurt E, Haas S, Stahler A, Heinemann V, Held S, Alig AHS, Kasper S, Stintzing S, Trarbach T, Modest DP. Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212). Eur J Cancer. 2022 Oct 25;178:37-48

Sommerhäuser G, Kurreck A, Stintzing S, Heinemann V, von Weikersthal LF, Dechow T, Kaiser F, Karthaus M, Schwaner I, Fuchs M, König A, Roderburg C, Hoyer I, Quante M, Kiani A, Fruehauf S, Müller L, Reinacher-Schick A, Ettrich TJ, Stahler A, Modest DP Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer..BMC Cancer. 2022 Jul 27;22(1):820

Stahler A, Stintzing S, von Einem JC, Westphalen Benedikt CB, Heinrich K, Krämer N, Michl M, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Heintges T, Kahl C, Kullmann F, Scheithauer W, Moehler M, Kaiser F, Kirchner T, Jung A, Heinemann V. Corrigendum to 'Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial'. [European Journal of Cancer 137 (2020) 250-259]. Eur J Cancer. 2022 Jul;169:223-225.

Stahler A, Modest DP, Fischer von Weikersthal L, Kaiser F, Decker T, Held S, Graeven U, Schwaner I, Denzlinger C, Schenk M, Kurreck A, Heinrich K, Gießen-Jung C, Neumann J, Kirchner T, Jung A, Stintzing S, Heinemann V. First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110). Eur J Cancer. 2022 Sep;173:194-203.

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109). Kurreck, A., Geissler, M., Martens, U. M., Riera-Knorrenschild, J., Greeve, J., Florschütz, A., Wessendorf, S., Ettrich, T., Kanzler, S., Nörenberg, D., Seidensticker, M., Held, S., Buechner-Steudel, P., Atzpodien, J., Heinemann, V., Stintzing, S., Seufferlein, T., Tannapfel, A., Reinacher-Schick, A. C. and Modest, D. P. (2020). J Cancer Res Clin Oncol 146(10): 2681-2691.

RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. Arai, H., Cao, S., Battaglin, F., Wang, J., Kawanishi, N., Tokunaga, R., Loupakis, F., Stintzing, S., Soni, S., Zhang, W., Mancao, C., Salhia, B., Mumenthaler, S. M., Cremolini, C., Heinemann, V., Falcone, A., Millstein, J. and Lenz, H. J. (2021).  Mol Cancer Ther 20(6): 1153-1160.

BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. Cohen, R., Liu, H., Fiskum, J., Adams, R., Chibaudel, B., Maughan, T. S., Van Cutsem, E., Venook, A., Douillard, J. Y., Heinemann, V., Ja Punt, C., Falcone, A., Bokemeyer, C., Kaplan, R., Lenz, H. J., Koopman, M., Yoshino, T., Zalcberg, J., Grothey, A., de Gramont, A., Shi, Q. and André, T. (2021).  J Natl Cancer Inst 113(10): 1386-1395.

Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111) Ettrich, T. J., Perkhofer, L., Decker, T., Hofheinz, R. D., Heinemann, V., Hoffmann, T., Hebart, H. F., Herrmann, T., Hannig, C. V., Büchner-Steudel, P., Güthle, M., Hermann, P. C., Berger, A. W. and Seufferlein, T. (2021). Int J Cancer 148(6): 1428-1437.

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). Modest, D. P., Karthaus, M., Fruehauf, S., Graeven, U., Müller, L., König, A. O., Fischer von Weikersthal, L., Caca, K., Kretzschmar, A., Goekkurt, E., Haas, S., Kurreck, A., Stahler, A., Held, S., Jarosch, A., Horst, D., Reinacher-Schick, A., Kasper, S., Heinemann, V., Stintzing, S. and Trarbach, T. (2021). J Clin Oncol: Jco2101332.

Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). Stahler A, Heinemann V, Schuster V, Heinrich K, Kurreck A, Gießen-Jung C, Fischer von Weikersthal L, Kaiser F, Decker T, Held S, Graeven U, Schwaner I, Denzlinger C, Schenk M, Neumann J, Kirchner T, Jung A, Kumbrink J, Stintzing S, Modest DP. Eur J Cancer. 2021 Sep 7;157:71-80. doi: 10.1016/j.ejca.2021.08.017. Online ahead of print.

Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).  Stahler A, Heinemann V, Holch JW, von Einem JC, Westphalen CB, Heinrich K, Schlieker L, Jelas I, Alig AHS, Fischer LE, Weiss L, Modest DP, von Weikersthal LF, Decker T, Kiani A, Moehler M, Kaiser F, Kirchner T, Jung A, Stintzing S. Int J Cancer. 2021 Dec 1;149(11):1935-1943. doi: 10.1002/ijc.33747. Epub 2021 Jul 31.

Relationships Between Köhne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer. Sartore-Bianchi A, García-Alfonso P, Geissler M, Köhne CH, Peeters M, Price T, Valladares-Ayerbes M, Zhang Y, Burdon P, Taieb J, Modest DP. Clin Colorectal Cancer. 2021 May 25:S1533-0028(21)00049-9.

NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature. Osumi H, Vecchione L, Keilholz U, Vollbrecht C, Alig AHS, von Einem JC, Stahler A, Striefler JK, Kurreck A, Kind A, Modest DP, Stintzing S, Jelas I. Eur J Cancer. 2021 Aug;153:86-95. doi: 10.1016/j.ejca.2021.05.010. Epub 2021 Jun 18.

Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). Heinrich K, Modest DP, Ricard I, Fischer von Weikersthal L, Decker T, Kaiser F, Graeven U, Uhlig J, Schenk M, Freiberg-Richter J, Peuser B, Denzlinger C, Giessen-Jung C, Stahler A, Michl M, Held S, Jung A, Kirchner T, Stintzing S, Heinemann V. Eur J Cancer. 2021 Apr;147:128-139. doi: 10.1016/j.ejca.2021.01.025. Epub 2021 Feb 27.

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Held S, Miller-Phillips L, Modest DP, Jung A, Kirchner T, Stintzing S. Br J Cancer. 2021 Feb;124(3):587-594. doi: 10.1038/s41416-020-01140-9. Epub 2020 Nov 6.

Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials. Stahler A, Stintzing S, Modest DP, Ricard I, Giessen-Jung C, Kapaun C, Ivanova B, Kaiser F, Fischer von Weikersthal L, Moosmann N, Schalhorn A, Stauch M, Kiani A, Held S, Decker T, Moehler M, Neumann J, Kirchner T, Jung A, Heinemann V. Clin Cancer Res. 2020 Dec 15;26(24):6559-6567. doi: 10.1158/1078-0432.CCR-20-2748. Epub 2020 Sep 17.

Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306. Froelich MF, Petersen EL, Heinemann V, Nörenberg D, Hesse N, Gesenhues AB, Modest DP, Sommer WH, Hofmann FO, Stintzing S, Holch JW. Clin Colorectal Cancer. 2020 Dec;19(4):291-300.e5. doi: 10.1016/j.clcc.2020.06.005. Epub 2020  Jun 22.

Automated detection of microsatellite status in early colon cancer (CC) using artificial intelligence (AI) integrated infrared (IR) imaging on unstained samples from the AIO ColoPredictPlus 2.0 (CPP) registry study. Großerüschkamp F, Schörner SM, Kraeft A-L, et al.  Ann of oncology, VOLUME 32, SUPPLEMENT 5, S531-S532, SEPTEMBER 01, 2021, DOI:https://doi.org/10.1016/j.annonc.2021.08.907 385O

Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials Noepel-Duennebacke S, Juette H, Schulmann K, Graeven U,. Porschen R, Stoehlmacher J, Hegewisch-Becker S, Raulf A, Arnold D, Reinacher-Schick A, Tannapfel A. J Cancer Res Clin Oncol. 2021 Oct;147(10):3063-3072. doi: 10.1007/s00432-021-03559-w.

Einfluss der Molekularpathologie auf die onkologische Chirurgie des kolorektalen Karzinoms [Influence of molecular markers on oncological surgery of colorectal cancer]. Nöpel-Dünnebacke S, Conradi LC, Reinacher-Schick A, Ghadimi M. Chirurg. 2021 Aug 27. German. doi: 10.1007/s00104-021-01486-7. Epub ahead of print.

Histopathologic Regression and Survival in RAS Wildtype Metastatic Colorectal Cancer Under First-Line Treatment – Subgroup Analysis of the  VOLFI Trial (AIO-KRK-0109)  Stefanie Noepel-Duennebacke, Henrik Juette Celine Lugnier, Dominik Paul  Modest, Uwe Martens,Renate Klaassen-Mielke, Volker Heinemann, Thomas Seufferlein, Michael Geissler, Andrea Tannapfel, Anke Reinacher-Schick, Iris Tischof International Journal of Clinical Oncology and Cancer Research 2021; 6(3): 130-135

Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial. Lueong SS, Herbst A, Liffers ST, Bielefeld N, Horn PA, Tannapfel A, Reinacher-Schick A, Hinke A, Hegewisch-Becker S, Kolligs FT, Siveke JT. Clin Chem. 2020 Dec 1;66(12):1510-1520. doi: 10.1093/clinchem/hvaa223. PMID: 33257977.

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. Alexander Stein, Donjete Simnica , Christoph Schultheiß , Rebekka Scholz, Joseph Tintelnot, Eray Gökkurt, Lisa von Wenserski, Edith Willscher, Lisa Paschold , Markus Sauer, Sylvie Lorenzen, Jorge Riera-Knorrenschild, Reinhard Depenbusch, Thomas J Ettrich, Steffen Dörfel, Salah-Eddin Al-Batran, Meinolf Karthaus, Uwe Pelzer, Lisa Waberer, Axel Hinke, Marcus Bauer, Chiara Massa, Barbara Seliger, Claudia Wickenhauser, Carsten Bokemeyer, Susanna Hegewisch-Becker, Mascha Binder, J Immunother Cancer 2021;9:e002844. doi:10.1136/jitc-2021-002844,

Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial Rebekka Kosmala, Emmanouil Fokas, Michael Flentje, Rolf Sauer, Torsten Liersch, Ullrich Graeven, Rainer Fietkau, Werner Hohenberger, Dirk Arnold, Ralf-Dieter Hofheinz, Michael Ghadimi, Philipp Ströbel, Ludger Staib, Gerhard G Grabenbauer, Gunnar Folprecht, Simon Kirste, Wolfgang Uter, Christine Gall, Claus Rödel, Bülent Polat, of the German Rectal Cancer Study Group Eur J Cancer 2021 Feb;144:281-290. doi: 10.1016/j.ejca.2020.11.029. Epub 2020 Dec 28.

Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies Lisa Salvatore, Emilio Bria, Isabella Sperduti, Axel Hinke, Susanna Hegewisch-Becker, Thomas Aparicio, Karine Le Malicot, Valérie Boige, Dieter Koeberle, Daniela Baertschi, Daniel Dietrich, Giampaolo Tortora, Dirk Arnold  Cancer Treat Rev 2021 Jun;97:102202. doi: 10.1016/j.ctrv.2021.102202. Epub 2021 Mar 30.

Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial. Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Fleischmann M, Fokas E, Rödel C. Radiother Oncol. 2021 Oct 4:S0167-8140(21)08749-1. doi: 10.1016/j.radonc.2021.09.028. Online ahead of print.

Importance and Qualitative Requirements of Magnetic Resonance Imaging for Therapy Planning in Rectal Cancer - Interdisciplinary Recommendations of AIO, ARO, ACO and the German Radiological Society. Attenberger UI, Clasen S, Ghadimi M, Grosse U, Antoch G, Schreyer AG, Wessling J, Hausmann D, Piso P, Plodeck V, Stintzing S, Rödel CM, Hofheinz RD. Rofo. 2021 May;193(5):513-520. doi: 10.1055/a-1299-1807

Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. Schmoll HJ, Stein A, Van Cutsem E, Price T, Hofheinz RD, Nordlinger B, Daisne JF, Janssens J, Brenner B, Reinel H, Hollerbach S, Caca K, Fauth F, Hannig CV, Zalcberg J, Tebbutt N, Mauer ME, Marreaud S, Lutz MP, Haustermans K. J Clin Oncol. 2021 Jan 1;39(1):17-29

Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial. Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rödel C, Fokas E. JAMA Oncol. 2020 Sep 1;6(9):1416-1421.

Attenberger U, Rödel C, Ghadimi M, Piso P, Arnold D, Folprecht G, Geissler M, Hegewisch-Becker S, Heinemann V, Kasper S, Modest D, Reinacher-Schick A, Seufferlein T, Stein A, Stintzing S, Hofheinz RD. Prerequisites of magnetic resonance imaging for treatment planning in locally advanced rectal cancer - Interdisciplinary recommendations.  Z Gastroenterol. 2020 Jun;58(6):577-582

 

Berger MD, Ning Y, Stintzing S, Heinemann V, Cao S, Zhang W, Yang D, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Tokunaga R, Naseem M, Battaglin F, Cremolini C, Falcone A, Loupakis F, Lenz HJ. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.  Eur J Cancer. 2020 May;131:89-97. doi: 10.1016/j.ejca.2020.02.048. Epub 2020 Apr 16. PMID: 32305727 Free PMC article.

Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rödel C, Fokas E. Association of Sex With Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer.  JAMA Oncol. 2020 Feb 1;6(2):294-296.

Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rödel C, Fokas E. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.  JAMA Oncol. 2020 Jul 9;6(9):1416-21.

Diefenhardt M, Hofheinz RD, Martin D, Beißbarth T, Arnold D, Hartmann A, von der Grün J, Grützmann R, Liersch T, Ströbel P, Grabenbauer GG, Rieger M, Fietkau R, Graeven U, Weitz J, Folprecht G, Ghadimi M, Rödel F, Rödel C, Fokas E; German Rectal Cancer Study Group. Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial.  Int J Cancer. 2019 Oct 15;145(8):2282-2291.

Ettrich TJ, Perkhofer L, Decker T, Hofheinz RD, Heinemann V, Hoffmann T, Hebart HF, Herrmann T, Hannig CV, Büchner-Steudel P, Güthle M, Hermann PC, Berger AW, Seufferlein T. Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111).  Int J Cancer. 2020 Sep 15. doi: 10.1002/ijc.33296

Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Schmiegel W, Jacobasch L, Weitz J, Folprecht G, Schlenska-Lange A, Flentje M, Germer CT, Grützmann R, Schwarzbach M, Paolucci V, Bechstein WO, Friede T, Ghadimi M, Hofheinz RD, Rödel C; German Rectal Cancer Study Group. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12.  J Clin Oncol. 2019 Dec 1;37(34):3212-3222.

Froelich MF, Petersen EL, Heinemann V, Nörenberg D, Hesse N, Gesenhues AB, Modest DP, Sommer WH, Hofmann FO, Stintzing S, Holch JW. Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306.  Clin Colorectal Cancer. 2020 Jun 22:S1533-0028(20)30090-6. doi: 10.1016/j.clcc.2020.06.005. Online ahead of print. PMID: 32917529

Holch JW, Held S, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser F, Heintges T, Kahl C, Kullmann F, Scheithauer W, Moehler M, von Einem JC, Michl M, Heinemann V. Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).  Ann Oncol. 2020 Jan;31(1):72-78. doi: 10.1016/j.annonc.2019.10.001. PMID: 31912799

S.S. Lueong, A. Herbst, S. Liffers, N. Bielefeld, P.A. Horn, A. Tannapfel, A. Reinacher-Schick, A. Hinke, S. Hegewisch-Becker, F.T. Kolligs and J.T. Siveke, Serial circulating tumor DNA mutational status in patients with KRAS- mutant metastatic colorectal cancer from the phase 3 AIO KRK0207 trial, Clinical Chemistry  Article Doi: 10.1093/clinchem/hvaa223, accepted for publication

Modest DP, Heinemann V, Folprecht G, Denecke T, Pratschke J, Lang H, Bemelmans M, Becker T, Rentsch M, Seehofer D, Bruns CJ, Gebauer B, Held S, Stahler A, Heinrich K, von Einem JC, Stintzing S, Neumann UP, Ricard I. Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306.  Ann Surg Oncol. 2020 Jul;27(7):2389-2401. doi: 10.1245/s10434-020-08219-w. Epub 2020 Mar 14. PMID: 32172334 Free PMC article.

Noepel-Duennebacke S, Juette H, Feder IS, Kluxen L, Basara N, Hiller W, Herzog T, Klaassen-Mielke R, Mueller L, Senkal M, Engel L, Teschendorf C, Trenn G, Verdoodt B, Wolters H, Uhl W, Reinacher-Schick A, Tannapfel A. High microsatellite instability (MSI-H) is associated with distinct clinical and molecular characteristics and an improved survival in early Colon cancer (CC); real world data from the AIO molecular registry Colopredict Plus. Z Gastroenterol. 2020 Jun;58(6):533-541. doi: 10.1055/a-1156-4433. Epub 2020 Jun 16. PMID: 32544965 English.

S. Nöpel-Dünnebacke, R. Klaassen-Mielke, I.S. Feder, N. Timmesfeld, A. Reinacher-Schick, A. Tannapfel ESMO ABSTRACT ONLY| VOLUME 31, SUPPLEMENT 4, S415, SEPTEMBER 01, 2020 409P Causes of mortality in elderly UICC stage III colon cancer (CC) patients (pts.) - Tumor related death and competing risks from the Colopredict Plus (CPP) registry DOI: https://doi.org/10.1016/j.annonc.2020.08.520

Schmoll HJ, Stein A, Van Cutsem E, Price T, Hofheinz RD, Nordlinger B, Daisne JF, Janssens J, Brenner B, Reinel H, Hollerbach S, Caca K, Fauth F, Hannig CV, Zalcberg J, Tebbutt N, Mauer ME, Marreaud S, Lutz MP, Haustermans K., Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD.  J Clin Oncol. 2020 Oct 1:JCO2001740.

Schulz C, Heinemann V, Heinrich K, Haas M, Holch JW, Fraccaroli A, Held S, von Einem JC, Modest DP, Fischer von Weikersthal L, Kullmann F, Moehler M, Scheithauer W, Jung A, Stintzing S. Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.  Anticancer Drugs. 2020 Sep;31(8):856-865. doi: 10.1097/CAD.0000000000000965. PMID: 32639280

Stahler A, Stintzing S, von Einem JC, Westphalen CB, Heinrich K, Krämer N, Michl M, Modest DP, von Weikersthal LF, Decker T, Kiani A, Heintges T, Kahl C, Kullmann F, Scheithauer W, Moehler M, Kaiser F, Kirchner T, Jung A, Heinemann V. Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.  Eur J Cancer. 2020 Sep;137:250-259. doi: 10.1016/j.ejca.2020.07.003. Epub 2020 Aug 15. PMID: 32810748

Stintzing S, Wirapati P, Lenz HJ, Neureiter D, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser F, Al-Batran S, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Held S, Modest DP, Jung A, Kirchner T, Aderka D, Tejpar S, Heinemann V. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.  Ann Oncol. 2019 Nov 1;30(11):1796-1803. doi: 10.1093/annonc/mdz387. PMID: 31868905 Free PMC article. Clinical Trial.

Stintzing S, van Oostrum I, Pescott CP, Ronga P, Heeg B, Heinemann V. Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study.  J Med Econ. 2020 May;23(5):448-455. doi:  10.1080/13696998.2019.1709848. Epub 2020 Jan 17. PMID: 31903807